Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Argus Health
QuintilesIMS
Johnson and Johnson
Baxter
UBS
Covington
Julphar

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIOCIGUAT

« Back to Dashboard

Clinical Trials for Riociguat

Trial ID Title Status Sponsor Phase Summary
NCT00855660 Effect of Riociguat on Bone Metabolism Completed Bayer Phase 1 Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.
NCT01014247 Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation Completed Bayer Phase 1 The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).
NCT01065051 Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics Terminated Bayer Phase 2 The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Riociguat

Condition Name

Condition Name for Riociguat
Intervention Trials
Hypertension, Pulmonary 12
Ventricular Dysfunction, Left 3
Chronic Thromboembolic Pulmonary Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Riociguat
Intervention Trials
Hypertension, Pulmonary 18
Hypertension 17
Familial Primary Pulmonary Hypertension 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Riociguat

Trials by Country

Trials by Country for Riociguat
Location Trials
United States 104
Germany 60
Japan 34
Italy 23
United Kingdom 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Riociguat
Location Trials
Massachusetts 8
Ohio 7
New York 7
Colorado 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Riociguat

Clinical Trial Phase

Clinical Trial Phase for Riociguat
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Riociguat
Clinical Trial Phase Trials
Recruiting 12
Completed 9
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Riociguat

Sponsor Name

Sponsor Name for Riociguat
Sponsor Trials
Bayer 26
Merck Sharp & Dohme Corp. 2
Medical University of Vienna 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Riociguat
Sponsor Trials
Industry 28
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
AstraZeneca
Healthtrust
Mallinckrodt
Chinese Patent Office
Johnson and Johnson
Federal Trade Commission
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.